What Does It Mean to Be HLA Class 2 Antibody Positive?

Testing positive for HLA class II antibodies means your immune system has developed antibodies that recognize and target a specific group of proteins found on certain cells in other people’s bodies. These proteins, part of the human leukocyte antigen (HLA) system, help the immune system distinguish “self” from “foreign.” Having these antibodies does not mean you are sick; it means your body has been exposed to foreign HLA class II molecules at some point and has built a memory response against them. The result matters most if you ever need an organ transplant, a stem cell transplant, or certain blood transfusions, because those antibodies can attack donated tissue that carries the matching proteins.

What HLA Class II Molecules Actually Do

Your cells display HLA molecules on their surface like identity tags. Class I HLA molecules sit on nearly every nucleated cell in your body. Class II molecules are more selective: they appear mainly on immune cells like B cells and antigen-presenting cells, and on activated endothelial cells lining blood vessels.

The class II family includes three main groups of genes: HLA-DR, HLA-DQ, and HLA-DP. Their job is to grab fragments of foreign proteins and present them to helper T cells, which then coordinate a broader immune response. When your immune system encounters class II molecules from another person, it can recognize them as foreign and produce antibodies against them. Those antibodies are what a lab report refers to when it says you are “HLA class II antibody positive.”

How People Develop These Antibodies

Three main life events account for the vast majority of HLA sensitization: pregnancy, blood transfusions, and prior organ or tissue transplants. Each exposes your immune system to someone else’s HLA molecules.

Pregnancy is the most common route for class II antibody development. During pregnancy, a mother’s immune system encounters the father’s HLA molecules expressed on fetal cells. With each successive pregnancy, exposure increases. Research has shown that maternal anti-HLA class I and class II antibody levels rise with the number of pregnancies and births.

Blood transfusions are another significant sensitizing event, because donor white blood cells carry HLA molecules. In one study, more than half of patients who received standard (non-leukoreduced) blood products developed class I HLA antibodies, and about half developed class II antibodies. When blood products were leukoreduced, meaning white blood cells were filtered out before transfusion, the rate of class II antibody development dropped dramatically to about 15%.¹ This is why leukoreduction has become standard practice in many countries: removing donor white blood cells from blood products prevents a significant share of HLA immunization.²

A previous transplant is the third major cause. When a transplanted organ eventually fails or is removed, the recipient often retains a strong antibody memory against the donor’s HLA molecules. This makes finding a compatible donor for a second transplant more difficult, because the patient’s immune system now reacts to a wider range of HLA types.

Why Class II Antibodies Matter in Kidney Transplantation

If you are waiting for a kidney transplant and your blood carries HLA class II antibodies directed against a potential donor’s specific HLA molecules, those antibodies are called donor-specific antibodies, or DSAs. Their presence before transplant is a red flag for rejection. In one study of kidney transplant recipients, patients who had DSAs with higher antibody strength at the time of surgery experienced acute rejection at a rate of 35%, compared to just 7% in those with low or undetectable levels.³

Antibodies that persist over time are especially dangerous. A study tracking kidney transplant outcomes found that patients whose preformed DSAs remained detectable after transplant faced roughly six times the risk of significant kidney function decline or graft loss compared to patients without DSAs. Patients who developed new DSAs after transplant (called de novo DSAs) faced about four and a half times the risk. But if preformed DSAs disappeared after surgery, outcomes were essentially the same as for patients who never had DSAs at all.⁴ That finding carries a reassuring message: being antibody positive does not automatically doom a transplant. What matters is whether those antibodies stick around and remain active against the donor’s tissue.

The DQ Problem

Not all class II antibodies carry the same risk. Among the three class II subtypes, HLA-DQ antibodies have emerged as a particular concern for long-term kidney transplant survival. In a study of kidney recipients, de novo DQ-specific DSAs were the only class II antibody type independently linked to late graft failure. DQ antibodies were also uniquely associated with chronic antibody-mediated rejection, a slow-burning form of immune injury that damages the transplant over months to years.⁵

Part of the reason DQ antibodies cause outsized trouble is that traditional matching protocols historically focused on HLA-A, -B, and -DR, largely ignoring DQ and DP. A patient could receive a kidney well-matched at DR but poorly matched at DQ, creating a setup for the immune system to produce new DQ-specific antibodies after transplant. Research into epitope-level matching, which looks at the fine structural features on HLA molecules rather than just broad antigen categories, suggests that better DQ and DR epitope matching could reduce the risk of de novo class II DSA development.⁶

HLA-DP antibodies, while less commonly tested for, are not harmless either. Case reports have documented acute and chronic antibody-mediated rejection driven solely by donor-specific HLA-DP antibodies, with no other DSAs present.⁷ These cases are uncommon but highlight that the entire class II family deserves attention in transplant planning.

Beyond Kidneys: Lungs, Liver, and Stem Cells

Class II antibodies cause problems across all types of solid organ and cell transplantation, though the specifics vary.

In lung transplantation, patients who develop de novo DSAs within the first month after surgery face significantly worse outcomes. Five-year survival in one study was 41% for patients with early de novo DSAs compared to 70% for those without, and high-strength DSAs at one month were an independent risk factor for death.⁸

Liver transplants have long been considered somewhat resistant to antibody-mediated injury compared to kidneys, but class II antibodies still matter. In a large cohort, about 8% of liver transplant recipients developed de novo DSAs within the first year. Strikingly, 95% of those new antibodies were directed against class II antigens rather than class I.⁹ The liver’s relative tolerance does not mean class II DSAs can be ignored there.

In stem cell transplantation, class II antibodies pose a different threat: graft failure, where donated stem cells fail to engraft and produce new blood cells. A meta-analysis found that patients with anti-HLA DSAs before stem cell transplant had roughly seven and a half times the risk of primary graft failure compared to patients without them.¹⁰ The risk applied to both class I and class II antibodies, with no significant difference between them.¹¹

How the Test Works and Where It Can Mislead

HLA antibody testing is usually done with a technology called Luminex single-antigen bead assays. Tiny beads are coated with individual HLA molecules, your serum is added, and the lab measures whether your antibodies latch onto any of them. Results are reported as a mean fluorescence intensity (MFI) value: higher numbers mean stronger antibody binding to a particular HLA type.

The test is sensitive but not perfect. One known pitfall involves antibodies that react with denatured (misfolded) HLA class II molecules stuck to the beads rather than with the intact, native form of those molecules. Because the denatured forms expose protein regions that would normally be hidden, these “false-positive” reactions can make it look like you have clinically relevant antibodies when you do not. Follow-up testing with flow cytometry crossmatch and absorption experiments can sort out these artifacts.¹²

Transplant programs also use virtual crossmatching, where the patient’s known antibody profile is compared against the donor’s HLA type using a computer database, to predict compatibility before performing a physical laboratory crossmatch. Studies have shown that the virtual approach and the physical crossmatch generally agree well, though older physical crossmatch methods can underperform the more detailed virtual analysis.¹³

Beyond simple detection, newer assays check whether the antibodies can activate complement, a part of the immune system that amplifies tissue damage. One such test measures C3d binding. In kidney transplant patients with antibody-mediated rejection, the presence of C3d-binding DSAs was associated with a higher risk of graft loss than DSAs that did not bind C3d.¹⁴ The strength of the antibody on the standard bead assay does not always predict whether it will fix complement; in pediatric kidney recipients, MFI values correlated poorly with complement-fixing ability.¹⁵ This means a moderate-strength antibody could be more dangerous than a strong one, depending on its complement-activating behavior.

What Can Be Done About It

Being HLA class II antibody positive does not mean transplantation is off the table. Several strategies exist to work around or reduce the antibody barrier.

Desensitization is the most direct approach. It typically involves plasmapheresis (filtering antibodies from the blood) combined with intravenous immunoglobulin (IVIG). In a study of stem cell transplant patients with DSAs, this combination reduced the strongest antibody levels by a median of more than 5,000 MFI units, and over half of treated patients cleared all detectable DSAs by shortly after transplant. Survival outcomes for desensitized patients were similar to those of patients who never had DSAs, and substantially better than for patients whose DSAs went untreated.¹⁶

Desensitization does not always work, though. In highly sensitized lung transplant candidates with broad, strong antibody panels, an aggressive multi-modal desensitization protocol did not significantly reduce overall HLA antibody levels, only producing a modest decline in antibodies of moderate strength.¹⁷ Patients who are broadly sensitized, reacting to a large proportion of the population’s HLA types, face the hardest road.

For those patients, kidney paired exchange (also called kidney swap programs) offers an alternative. If a willing living donor is incompatible with their intended recipient because of HLA antibodies, the pair can enter a registry where they swap donors with another incompatible pair. This sidesteps the antibody problem by finding a donor the recipient’s antibodies do not target. Studies have shown that paired exchange programs significantly reduce the class I and class II epitope mismatch between donor and recipient.¹⁸ For the most broadly sensitized patients, a hybrid approach combining paired exchange with desensitization against the best-available donor may offer the greatest chance of a successful transplant.¹⁹

A newer drug called imlifidase, an enzyme that rapidly cleaves antibodies, has been used to enable transplantation in highly sensitized kidney patients. Five-year follow-up data from early treated patients show that class II DSA levels decreased over time from a mean MFI of about 18,900 before transplant to roughly 8,100 at five years, though most patients still had detectable class II DSAs.²⁰ The transplants survived, but ongoing antibody monitoring and immune suppression remain essential.

Class II Antibodies and Transfusion Reactions

Outside of transplantation, HLA class II antibodies are also implicated in transfusion-related acute lung injury (TRALI), a serious and sometimes fatal complication of blood transfusion. TRALI occurs when antibodies in donated blood react against the recipient’s white blood cells in the lungs, causing fluid buildup and breathing difficulty. Most attention historically focused on class I antibodies, but studies have confirmed that class II antibodies can trigger TRALI as well. Investigation of suspected TRALI cases should include testing donors for class II HLA antibodies alongside class I and granulocyte antibodies.²¹ This is one reason blood banks in many countries now preferentially use male donors or nulliparous (never-pregnant) female donors for plasma-rich products: women who have been pregnant are more likely to carry HLA antibodies that could trigger TRALI in a recipient.

Pregnancy, Placental Biology, and a Possible Protective Twist

Pregnancy is the most common source of HLA class II antibodies, but the consequences for the mother and child extend beyond future transplant eligibility. Recent research into a rare pregnancy complication called chronic histiocytic intervillositis (CHI), where the placenta becomes severely inflamed, found that HLA class II molecules were abnormally expressed on the outer layer of the placenta in affected pregnancies. The degree of class II expression correlated with the severity of placental inflammation and with deposition of complement, a marker of immune activation. Interestingly, the mothers of affected pregnancies did not have higher levels of circulating anti-HLA antibodies than healthy controls; the problem appeared to be at the tissue level rather than in the bloodstream.²²

On the flip side, there is evidence that maternal class II antibodies might offer a benefit to the child. One study found that mothers carrying anti-HLA class II antibodies were less likely to have children who developed allergies and seasonal hay fever by age eight. This association held for class II antibodies specifically, not class I. The mechanism behind this potential protective effect remains unclear, but it suggests the immune interplay between mother and fetus during pregnancy is more nuanced than a simple “sensitization is bad” story.²³

Do Viral Infections Create HLA Antibodies?

One concern that surfaces periodically is whether common viral infections could trigger HLA antibody production through molecular mimicry, where virus-specific antibodies accidentally cross-react with HLA molecules. If true, this could make HLA sensitization far more unpredictable, since viral exposures are nearly universal. However, laboratory testing of virus-specific antibodies against HLA class I and class II molecules, and HLA-specific antibodies against viral antigens, found no cross-reactivity in either direction.²⁴ While cross-reactive T cells between viruses and HLA molecules are well documented, the same phenomenon appears to be rare to nonexistent at the antibody level. For practical purposes, catching the flu or a cold is unlikely to make you HLA antibody positive.